The startup develops mass spectrometry detection kits that enhance diagnostic accuracy for conditions such as Alzheimer's, bladder cancer, and hormone-related disorders. By providing precise medical solutions, the company enables personalized healthcare through improved detection methods.
Funding
Funding not disclosed
Founders
Product
Problem
Current diagnostic methods for diseases like Alzheimer's, bladder cancer, and hormone imbalances often lack the precision needed for early and accurate detection. This can lead to delayed treatment and less effective patient outcomes.
Solution
The company develops mass spectrometry-based detection kits designed to improve the accuracy and speed of diagnosing complex conditions. These kits enable clinicians to identify disease biomarkers with greater sensitivity and specificity compared to traditional methods. By providing more precise diagnostic information, the company's technology supports personalized healthcare approaches, allowing for earlier intervention and tailored treatment plans. The kits are designed for ease of use in clinical laboratory settings, integrating seamlessly with existing mass spectrometry workflows.
Target Audience
The primary target audience includes clinical laboratories, hospitals, and research institutions involved in diagnostic testing and personalized medicine.
Features
- Mass spectrometry detection kits for Alzheimer's disease, bladder cancer, and hormone-related disorders
- Enhanced sensitivity and specificity in biomarker detection
- Streamlined workflow for integration into existing clinical laboratory settings
- Quantitative analysis of disease-specific analytes